Budapest, Hungary

József Reiter

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2001.


% Patents Active = 100.0

Average Co-Inventor Count = 18.0

ph-index = 1


Company Filing History:

goldMedal1 out of 834,411 
Other
 patents

Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: József Reiter: Innovator in Pharmaceutical Chemistry

Introduction

József Reiter is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on compounds that influence the central nervous system and the heart.

Latest Patents

József Reiter holds a patent for a novel class of compounds titled "2-(1,2,4-triazole-1-yl)-1,3,4-thiadiazole derivatives having an effect on the C.N.S. and the heart." This invention refers to unique derivatives that have a profound impact on both the heart and the central nervous system. The patent outlines pharmaceutical compositions containing these derivatives and details the processes for preparing these novel compounds.

Career Highlights

Throughout his career, József Reiter has focused on developing innovative pharmaceutical solutions. His work has led to advancements in the understanding and treatment of conditions affecting the heart and central nervous system. His dedication to research and development has positioned him as a key figure in his field.

Collaborations

József Reiter has collaborated with several professionals in his field, including József Barkóczy and Gábor Berecz. These collaborations have fostered a productive environment for innovation and have contributed to the success of his projects.

Conclusion

József Reiter's contributions to pharmaceutical chemistry through his innovative patents highlight his role as a significant inventor in the industry. His work continues to influence the development of new therapeutic compounds that can improve health outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…